- Previous Close
2.8900 - Open
2.8900 - Bid 2.1100 x 200
- Ask 3.6900 x 200
- Day's Range
2.8000 - 2.9900 - 52 Week Range
1.9100 - 48.7900 - Volume
106,393 - Avg. Volume
1,371,764 - Market Cap (intraday)
14.264M - Beta (5Y Monthly) 7.68
- PE Ratio (TTM)
-- - EPS (TTM)
-4.9900 - Earnings Date Nov 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.30
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
www.vivos.comRecent News: VVOS
View MorePerformance Overview: VVOS
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VVOS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VVOS
View MoreValuation Measures
Market Cap
13.97M
Enterprise Value
9.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.71
Price/Book (mrq)
1.82
Enterprise Value/Revenue
0.64
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-85.90%
Return on Assets (ttm)
-57.00%
Return on Equity (ttm)
-284.96%
Revenue (ttm)
14.02M
Net Income Avi to Common (ttm)
-12.04M
Diluted EPS (ttm)
-4.9900
Balance Sheet and Cash Flow
Total Cash (mrq)
6.9M
Total Debt/Equity (mrq)
27.79%
Levered Free Cash Flow (ttm)
-8.9M